NEPC

Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
KAT2B, Gene, Algorithm, Growth, AML, Carcinoma, DRIVE, Biomarker, Acute myeloid leukemia, Cancer, AI, Developmental biology, NEPC, Senior, Translation, AACR, Doctor of Philosophy, Neoplasm, Therapy, Machine learning, Annual general meeting, Vaccine

NEWTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The Company highlighted the distinct ability of its AURIGIN™ platform to identify both cell state plasticity, the proliferative state in which cancer cells grow, and the causative gene targets. In a second poster, Auron shared preclinical data from its program targeting KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML). These data led to the nomination of AUTX-703, an orally available and selective KAT2A/B degrader development candidate, for which Auron expects to file an IND in 2024.

Key Points: 
  • The Company highlighted the distinct ability of its AURIGIN™ platform to identify both cell state plasticity, the proliferative state in which cancer cells grow, and the causative gene targets.
  • In a second poster, Auron shared preclinical data from its program targeting KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML).
  • These data led to the nomination of AUTX-703, an orally available and selective KAT2A/B degrader development candidate, for which Auron expects to file an IND in 2024.
  • “The understanding that cellular plasticity contributes to aggressive and treatment-resistant tumor growth underscores the need for innovative, targeted approaches.

Auron Announces Poster Presentations at 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Neoplasm, AML, SCLC, AI, NEPC, Growth, Carcinoma, AACR, KAT2B, Doctor of Philosophy, Therapy, Machine learning, Acute myeloid leukemia, Research, Cancer, Mobile phone

Auron will share data demonstrating the ability of AURIGIN to identify drivers of tumor plasticity, a critical vulnerability of cancer cells that is associated with poor prognosis and treatment-resistance.

Key Points: 
  • Auron will share data demonstrating the ability of AURIGIN to identify drivers of tumor plasticity, a critical vulnerability of cancer cells that is associated with poor prognosis and treatment-resistance.
  • AURIGIN utilizes a single cell multi-omics atlas of human development and AI machine learning to identify the most relevant genetic targets in cancer cell plasticity.
  • Using AURIGIN to identify disrupted cell states, Auron is developing targeted treatments to revert cancer cells to a normal, quiescent state to stop tumor growth and proliferation.
  • At AACR, Auron will also present in vitro and in vivo data from its first-in-class, novel program targeting KAT2A/B, a histone acetyltransferase identified by AURIGIN that is associated with multiple tumor types.

Company Statement

Retrieved on: 
Friday, March 1, 2024
NEPC, Health, Outsourced, Credit

NEPC, an outside financial advisor to this plan since 2004, actively participates in the KRIPCO meetings.

Key Points: 
  • NEPC, an outside financial advisor to this plan since 2004, actively participates in the KRIPCO meetings.
  • KRIPCO chose NEPC to guide the plan through these turbulent times to ensure the health of the plan’s investment portfolio.
  • There can be no assurances that Kodak will receive excess assets from the plan or concerning the timing or amount of any such receipt.
  • Also, any amount received will be subject to material excise tax and other obligations.

Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform

Retrieved on: 
Thursday, February 8, 2024
AACR, SCLC, Growth, Cell, Acute myeloid leukemia, NEPC, AI, Phenotype, Gene, Biomarker, Patient, Carcinoma, AML, Doctor of Philosophy, Therapy, Tissue, Neoplasm, Cancer

NEWTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and treating disrupted cell states of cancer, today announced the nomination of its first development candidate, AUTX-703. Using its proprietary AURIGIN platform, Auron identified a key driver of tumor cell plasticity and discovered AUTX-703, a potent, selective, orally bioavailable small molecule degrader of that target. AUTX-703 is being developed for the treatment of patients with small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML).

Key Points: 
  • AUTX-703 is being developed for the treatment of patients with small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML).
  • In cancer, genetic or pathway alterations hijack normal development pathways to promote tumorigenesis by pushing cancer cells into a more plastic, proliferative cell state.
  • “One of the most significant challenges to effectively treating cancer is the ability of cancer cells to change their cellular identity.
  • The selection of AUTX-703 is an important step toward broadly applying our AURIGIN platform for the development of a range of next-generation targeted cancer therapies.”

Caris Life Sciences to Present Research at the 2024 ASCO Genitourinary Cancers Symposium

Retrieved on: 
Tuesday, January 23, 2024
Neutrophil, PST, Research, Overalls, Prostate cancer, Androgen receptor, University, Cancer, NCI, Prognosis, Metastasis, FACP, Transcriptome, MHC, Abstract, Diagnosis, Medicine, MYC, NK, Neoplasm, MAPK, DNA, Survival, HSD3B1, Disease, Drug development, ADT, E2F, Liver, PIM, Urachal cancer, Lung, POA, Physician, Renal cell carcinoma, PCA, B cell, Poster, RCC, Escape Room, AI, Immunotherapy, Recurrence, MBA, Prostate, Phenotype, PIM1, Gene expression, IL-6, Huntsman Cancer Institute, Patient, MD, Metadata, ASCO, WSP, C7, Society, PSA, FDA, NEPC, Vaccine

IRVING, Texas, Jan. 23, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present eight studies across four tumor types at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, January 25-27, 2024 in San Francisco. The findings demonstrate the continued and expanded capabilities of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • That's a major focus of the wide array of research Caris and our POA collaborators will proudly present at this year's ASCO GU."
  • The research is a collaboration with the Huntsman Cancer Institute at the University of Utah and other POA members.
  • Caris will present additional data from studies demonstrating the critical role of comprehensive molecular profiling in the treatment of genitourinary cancers.
  • The POA includes 90 cancer centers, academic institutions, research consortia and healthcare systems, including 42 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

Retrieved on: 
Tuesday, December 19, 2023
Prostate cancer, NEPC, NEN, SAN, Society, Therapy, Publication, Carcinoma, Half-life, SCLC, DLL3, Tea

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) being held in San Francisco, CA and virtually on January 25-27, 2024.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) being held in San Francisco, CA and virtually on January 25-27, 2024.
  • HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to kill tumor cells.
  • Details of the ASCO-GU presentation are as follows:
    Title: “Interim Results from a Phase 1/2 Study of HPN328, a Tri-Specific, Half-Life (T1/2) Extended DLL3-targeting T-Cell Engager in Patients with Neuroendocrine Prostate Cancer (NEPC) and other Neuroendocrine Neoplasms (NEN)”
    Session: Rapid Oral Abstract Session A: Prostate Cancer
    The presentation will also be available on Harpoon’s website under Publications following the session.
  • For more details about the ASCO-GU Annual Meeting, please visit: https://conferences.asco.org/gu/attend

Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Harpoon, SAN, PIPE, Therapy, Carcinoma, ASH, CRS, Cove, Exercise, ESMO, Patient, Research, Prostate cancer, AbbVie, DLL3, G&A, IMS, ORR, Development, RRMM, R, Oncology, BCMA, Society, NEPC, Cytokine release syndrome, Pharmaceutical industry, Cryptocurrency, Security (finance), Rare-earth element, SCLC

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.
  • Harpoon ended the third quarter of 2023 with $31.6 million in cash, cash equivalents, short-term marketable securities, compared to $53.1 million as of December 31, 2022.
  • Revenue for the third quarter ended September 30, 2023 was $4.5 million, compared to $13.6 million for the third quarter ended September 30, 2022.
  • Research and development (R&D) expense for the third quarter ended September 30, 2023 was $12.3 million, compared to $21.0 million for the third quarter ended September 30, 2022.

Celebrating Growth: NEPC Announces New 2024 Partners and Principals

Retrieved on: 
Thursday, December 7, 2023
Insurance, Construction & Property, Finance, Consulting, Banking, REIT, Accounting, Professional Services, Other Professional Services, Workforce, Partner, Growth, NEPC

NEPC, LLC one of the industry’s largest independent, research-driven investment consulting firms, today announced the election of six new partners and the promotion of five new principals across the firm.

Key Points: 
  • NEPC, LLC one of the industry’s largest independent, research-driven investment consulting firms, today announced the election of six new partners and the promotion of five new principals across the firm.
  • These new elections and promotions will be effective January 1, 2024.
  • “NEPC takes immense pride in nurturing and empowering our exceptional talent,” said Michael Manning , Managing Partner of NEPC.
  • The newly elected Partners are:
    For more information on NEPC’s employee workforce and to explore open opportunities, click here .

NEPC Survey Shows Defined Benefit Plans Are Focusing on Funded Position To Find Stability Amid Bearish View of Markets

Retrieved on: 
Thursday, November 9, 2023
Professional Services, Data Analytics, Insurance, Finance, Asset Management, Consulting, Accounting, Consultant, Federal, LDI, Federal Reserve, News, DB, Investment, Risk management, NEPC

This year’s data showcases that 53% of respondents have a bearish view of markets over the next 12 months.

Key Points: 
  • This year’s data showcases that 53% of respondents have a bearish view of markets over the next 12 months.
  • Respondent sentiment demonstrates a full reversal from the results of the 2021 survey , where 56% of respondents were bullish and 44% of respondents were bearish.
  • NEPC noted that clients are more focused on their funded status position rather than their portfolio’s absolute return amidst this period of macroeconomic market volatility.
  • 74% of plans in the 2023 Survey reported a funded status above 90%, a noticeable increase from 2021, where only 63% of plans were above 90% funded.

Summit Public Schools' Opacity Demonstrates Need for Oversight and Transparency in Digital Education Programs

Retrieved on: 
Thursday, September 21, 2023
University of Colorado Boulder, University, National Education Policy Center, Education, Bank statement, Curriculum, Policy, NEPC, Record, Research, Multimedia, Privacy, Language, Silicon, Student, Publication, SPS, Achievement Medal, Tutoring, Management, Online shopping

BOULDER, Colo., Sept. 21st, 2023 /PRNewswire-PRWeb/ -- Businesses can be expected to claim success. But when children's education and taxpayer dollars are at stake, reasonable transparency should also be expected.

Key Points: 
  • But when children's education and taxpayer dollars are at stake, reasonable transparency should also be expected.
  • Summit Public Schools provides a powerful example of inadequacies in policy related to transparency and accountability around school performance, digital educational programs, protection of student data, and school funding.
  • SPS's inability to provide records demonstrating the academic success it claims suggests the need for greater oversight of performance.
  • The new research brief from Molnar, Boninger, Noble, and Mani provides state policymakers with recommendations for oversight and accountability to protect the public interest and to ensure the transparency of digital educational programs.